A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset
Cancer Research and Treatment. 2020;52(2):530-542 
A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset
Radiotherapy and Oncology. 2017;124(3):403-410
A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients With Lower Grade Glioma in the Cancer Genome Atlas Dataset
International Journal of Radiation Oncology*Biology*Physics. 2017;99(2):E82
Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on The Cancer Genome Atlas Dataset
Frontiers in Molecular Biosciences. 2021;8:
PV-0233: A Radiosensitivity Gene Signature & PD-L1 Predict Clinical Outcome of Breast Cancer in TCGA dataset
Radiotherapy and Oncology. 2017;123:S117
A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma: Integrative Analyses of Transcriptome and Methylome
International Journal of Radiation Oncology*Biology*Physics. 2018;102(3):S49
PO-0714: A Radiosensitivity and PD-L1 Predict Clinical Outcome of Patients with GBM in TCGA Dataset
Radiotherapy and Oncology. 2018;127:S365
A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA
Radiotherapy and Oncology. 2018;128(2):245-253
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Journal of Pathology and Translational Medicine. 2017;51(1):40-48
GATA2 as an outcome signature: promoting bladder cancer migration and inhibiting PD-L1 expression
. 2022;